Coenzyme Q10 (CoQ) in Huntington's Disease (HD) (2CARE)

Study ID Alternative Stable ID Type
phs001065 Multicenter

Study Description

This is a multi-center, randomized, double-blind, placebo-controlled trial of CoQ involving 609 ambulatory subjects with HD who are not requiring skilled care or institutionalization. Eligible subjects were randomized to receive either CoQ 2400 mg/day or matching placebo. Subjects were followed prospectively and systematically for 60 months of double-blind observation. The primary outcome variable is a combination of time to death (for subjects who die) and the change from baseline to Month 60 in Total Functional Capacity (TFC) score (for subjects who survive). The primary hypothesis of the study is that chronic treatment of early-stage HD subjects with high-dosage CoQ will slow the progressive functional decline of HD.

Archive Link Archive Accession
dbGaP phs001065

Who archives the data?

There are no publications available